XTL Biopharma Regains Nasdaq Minimum Bid Price Compliance
Ticker: XTLB · Form: 6-K · Filed: Apr 2, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, listing, biotech
TL;DR
XTL Bio is back above $1 on Nasdaq, dodged delisting for now.
AI Summary
On April 2, 2024, XTL Biopharmaceuticals Ltd. received formal notification from the Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement of $1.00 per share. This follows a previous notice received on October 18, 2023, indicating the company had failed to meet this requirement.
Why It Matters
Regaining compliance with Nasdaq's minimum bid price requirement is crucial for XTL Biopharmaceuticals to maintain its listing on the exchange, avoiding potential delisting and preserving investor confidence.
Risk Assessment
Risk Level: medium — While regaining compliance is positive, the company previously failed to meet the requirement, indicating potential volatility in its stock price.
Key Numbers
- $1.00 — Minimum Bid Price (The threshold XTL Biopharmaceuticals needed to meet to regain compliance with Nasdaq listing rules.)
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — The company that received the Nasdaq notification.
- Nasdaq Stock Market, LLC (company) — The exchange that issued the compliance notice.
- $1.00 (dollar_amount) — The minimum bid price per share required by Nasdaq.
- April 2, 2024 (date) — The date XTL Biopharmaceuticals received the formal notice of compliance.
- October 18, 2023 (date) — The date XTL Biopharmaceuticals previously received a notice of non-compliance.
FAQ
What specific Nasdaq Listing Rule did XTL Biopharmaceuticals regain compliance with?
XTL Biopharmaceuticals regained compliance with Nasdaq Listing Rule 5550(a)(2), which pertains to the minimum bid price requirement.
When did XTL Biopharmaceuticals first receive notice of non-compliance from Nasdaq?
XTL Biopharmaceuticals first received a written notice from Nasdaq regarding failure to meet the minimum bid price on October 18, 2023.
What is the address of XTL Biopharmaceuticals' principal executive offices?
The address of XTL Biopharmaceuticals' principal executive offices is 5 Badner St. Ramat Gan, 4365603, Israel.
What is the filing type and date for this report?
This is a Form 6-K report, filed as of April 2, 2024.
What is the SIC code for XTL Biopharmaceuticals?
The Standard Industrial Classification (SIC) code for XTL Biopharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 271 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-04-02 16:05:21
Key Financial Figures
- $1.00 — Company that it had failed to meet the $1.00 per share minimum bid price requirement
Filing Documents
- ea0203182-6k_xtlbio.htm (6-K) — 9KB
- 0001213900-24-029320.txt ( ) — 10KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: April 2, 2024 XTL BIOPHARMACEUTICALS LTD. By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 2